Dermatology Market Worth $33.7 Billion by 2022

14 Jun, 2016, 04:00 ET from RnR Market Research

PUNE, India, June 14, 2016 /PRNewswire/ --

Global dermatology market growth to 2022 will be driven by a strong late-stage pipeline, which includes several highly valuable targeted therapies, such as dupilumab, AN-2729, AMG-827 and ixekizumab, according to this 2016 dermatology report now available with RnRMarketResearch.com.

Complete report on dermatology market spread across 144 pages discussing 11 key marketed products, leading company analysis and positioning is now available at http://www.rnrmarketresearch.com/global-dermatology-market-to-2022-innovative-pipeline-and-increasing-uptake-of-biologics-to-diversify-treatment-options-and-drive-strong-growth-market-report.html .

The global dermatology market will rise by more than 50% from $20 billion in 2015 to $33.7 billion by 2022, in spite of the patent expiries of many marketed monoclonal Antibodies (mAbs), which are unlikely to have a significant impact due to the practical and regulatory barriers faced by biosimilars. There exists a significant unmet need for improved treatment options across dermatology market indications, as physicians often cite poor efficacy, low patient compliance, and problematic safety profiles with the long-term use of many available treatments. This is especially true for patients with severe disease who rely on general immunosuppressive drugs.

There are currently a number of promising biologics in the pipeline for major skin disorders, including atopic dermatitis, acne vulgaris and rosacea, with 17 biologics in Phase III of development. This sizeable number suggests that they could have a considerable impact on treatment algorithms in the dermatology market therapy area over the forecast period. In terms of specific products, Regeneron/Sanofi's dupilumab is the leading candidate to bring about a paradigm shift in the treatment moderate-to-severe atopic dermatitis. At the same time, the use of older systemic immunosuppressants in dermatology market is likely to decrease once biologics for other key indications besides psoriasis enter the market from 2016.

However, this 2016 dermatology market research believes that the space is not likely to experience major shifts in terms of its big players by 2022. Key market players, namely Johnson & Johnson, AbbVie, Amgen, Novartis, and Roche, are expected to maintain their strong dermatology market shares throughout the forecast period, despite the fact that many of the approaching patent expiries - especially AbbVie's Humira and Johnson & Johnson's Remicade - will affect these companies directly.

Major marketed products from dermatology market discussed in this 2016-2022 research report include Humira (adalimumab), Remicade (infliximab), Enbrel (etanercept), Stelara (ustekinumab), Neoral (cyclosporine), Protopic (tacrolimus),  Elidel (pimecrolimus), Elocon (mometasone furoate),  Differin (adapalene), Metolate (methotrexate) and Clobex (clobetasol propionate). Order a copy of Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=604255 .

On a related note, another market research report titled Global Dermatology Partnering 2010-2016: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the dermatology partnering deals and agreements entered into by the world's leading healthcare companies. The report presents financial deal terms values for Dermatology market deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyze and benchmark the value of current deals. The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2010. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Access to over 700 dermatology market deal records and more are available in this research report at http://www.rnrmarketresearch.com/dermatology-partnering-terms-and-agreements-market-report.html .

Explore more reports on dermatology therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com


SOURCE RnR Market Research